IVL-Facilitated Transfemoral TAVR
Study Now Published
MINIMIZE TRAUMA – Minimize trauma to soft tissue by safely selecting and fracturing intimal and medial calcium
OPTIMIZE OUTCOMES – Optimize outcomes while reducing complications and cost escalation
SIMPLIFY PROCEDURES – Simple and intuitive system that makes complex calcified procedures more predictable
The First Applications of
Learn more about the potential of IVL in patients with aortic stenosis (AS) or IVL as a means to facilitate transfemoral access and avoid alternative routes by clicking on one of the below:
Too bad our coronary technology is not yet approved in the United States. Good news is that we have initiated our U.S. FDA IDE study. Learn more about the Disrupt CAD III study on our clinical research portion of the website.
All too familiar with the challenges of #EccentricCalcium? Int'l cardiologists can learn more about #ShockwaveIVL s… https://t.co/svd0NPNn5p
A huge thank you to Drs. @HontonB @JEscaned & Michael Lee for leading an excellent #PCReCourse symposium on real-wo… https://t.co/NhywifAz9e
Read the Q&A with Dr. @sahilparikhmd, corresponding author on the @CCIJournal Peripheral #ShockwaveIVL Meta-Analysi… https://t.co/eNX7AAHGAV
Learn more about the Unique Applications of #ShockwaveIVL in Iliac Occlusive Disease, #CLI and Large Bore Access fo… https://t.co/wwIHC3TN8y
Great publication by Dr. Ole De Backer and post by @CCIJournal sharing the feasibility & safety of a fully percutan… https://t.co/TGYuxlNnAg
It’s Good to Be Eccentric…When Treating #EccentricCalcium! Int'l operators can learn more about #ShockwaveIVL safet… https://t.co/mb8UP3QBfF
For int'l interventionalists who weren’t able to join the #PCReCourse live last week, here’s your opportunity to le… https://t.co/B5MA7Y6gR1
Excellent standalone #ShockwaveIVL case by Dr. Sanjeev Trehan in Tulsa, OK! Calcified #popliteal treated with 6.0x6… https://t.co/E86Ua3SVpR
It’s the 101 on whether you’re 1,1,1 1,0,1 or 0,1,0…learn from the international rockstars on how-to-treat calcific… https://t.co/oJilko7zl0
Hear from Dr. @sahilparikhmd on the Peripheral #IVL Meta-Analysis Publication by @CCIJournal, confirming the safety… https://t.co/7FTriCBDst
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
Too bad our coronary technology is not yet approved in the United States. Good news is that we have initiated our U.S. FDA IDE study. Learn more about the Disrupt CAD III study on our clinical research portion of the website.
